

Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need

To the Editor,

In chronic urticaria (CU) and recurrent angioedema (RAE), the need for effective treatment is high. The goals are for patients to have no signs and symptoms, normal quality of life (QoL), and complete disease control. Disease activity is assessed using scores such as the urticaria and the angioedema activity scores, that is, patient-reported outcome measures (PROMs) that rely on the daily documentation, by patients, of wheals and itch and of angioedema, respectively. This is complemented by the regular assessment of QoL and disease control with suitable PROMs, for example, the urticaria control test (UCT) or the angioedema control test (AECT).¹

Apps are ideally suited for documentation of the patients' daily signs and symptoms and regular assessments of their QoL and disease control. Apps can also help to identify relevant triggers (eg, stress and infections), consequences (eg, sleep impairment, missing work, or school), and comorbidities, a major need in CU and RAE. Moreover, apps can optimize treatment by individualizing therapy in order to reach goals.

However, the availability and functionality of apps for the self-evaluation of CU and RAE are unknown. To address this knowledge gap, we developed and applied an automatic search algorithm for self-evaluation apps for CU and RAE in Apple App and Google Play stores.

We used the methods that we had previously applied to asthma and anaphylaxis.² The search was performed in July 2021 (Figure 1). Briefly, we first designed the search algorithm to include seven search terms, each in three languages, that is, English, German, and Spanish (Table S1), then used the algorithm to search the app stores in 16 countries (Table S2), and finally assessed the apps identified for eligibility, that is, helping patients to track their signs and symptoms and manage their disease, by integrating information on triggers, consequences, comorbidities, and/or treatment. Our manual search, performed in parallel, used the same search terms, app stores, languages, countries, and eligibility criteria (Table 1). The apps were then assessed for their availability, functions, and features.

Our automatic and manual searches both identified the same nine apps for CU and/or RAE self-evaluation (Table 1): (a) four for hereditary angioedema (HAE), that is, Advance HAE, HAERO, myHAE, and HAE & me, none of which allow for tracking of wheals or itch, and (b) five for CU, that is, TARGET My Hives, UrCare, UrticariApp, and SymTrac™ HIVES (Table 1). All apps can be used to document signs and symptoms, an inclusion criterion of our search. Of the nine apps, six allowed for the documentation of triggers, three for PROM-based disease-driven impact, six for treatment, and one for disease control. Only one app was available in more than two languages, and none covered comorbidities or provided individualized advice (Table 1).

Our findings demonstrate that currently available iOS/Android apps for the self-evaluation of CU and RAE are very limited in number, function, and geographical reach, and that none cover comorbidities. Use of the same approach in asthma and anaphylaxis showed very similar results. The results of the UCARE CURICT study demonstrated that most CU patients, especially those with higher education and in rural areas, are interested in the use of digital tools for their health care.^{3,4} Clearly, better apps are needed and wanted.

Taken together, we identified a major unmet need in CU and RAE: that of the lack of suitable apps for patients to (a) self-evaluate their disease activity, impact, and control, (b) improve the self-management of their condition by recognizing important triggers of exacerbation, comorbidities, and consequences of their disease, and (c) optimize their therapy including allergic comorbidities. Novel apps that allow patients to do this are needed globally. Such apps are expected to improve the management of CU and RAE and may also serve as important tools for CU and RAE research.

KEYWORDS

apple, automatic search, google, itch, javascript, swelling, wheals




FIGURE 1 Search and exclusion criteria

FUNDING INFORMATION

Uriach Pharma; GSK; Allakos; Innate Pharma; Leo Pharma; Menarini; Novartis; Roche

CONFLICT OF INTEREST

Dr. Antó has nothing to disclose. Rasmus Maurer has nothing to disclose. Dr. Gimenez-Arnau reports grants and personal fees from Uriach Pharma, grants, personal fees and other from NOVARTIS PHARMA, personal fees from SANOFI - REGENERON, personal fees from AMGEN, grants and personal fees from GSK, personal fees from THERMO FISHER, personal fees from ALMIRALL, grants

from CARLOS III FEWDER, personal fees from AVENE, personal fees and other from LEO, outside the submitted work. Dr. Cherrez-Ojeda reports grants from Universidad Espiritu Santo, personal fees from Sanofi, outside the submitted work. Dr. Hawro has nothing to disclose. Dr. Magerl reports personal fees and non-financial support from Shire / Takeda, personal fees and non-financial support from CSL Behring, personal fees from Pharming, personal fees and non-financial support from Biocryst, personal fees from Kalvista, personal fees from Octapharma, personal fees from Novartis, outside the submitted work. Dr. Metz reports personal fees from Novartis, personal fees from Sanofi, personal fees from Celldex, personal fees

TABLE 1 Available apps for the self-evaluation of urticaria and angioedema

Name of App	For	App store(s) availability	Signs and symptoms	Triggers	Impact	Comorbidities	Medication	Advice	Languages	Made by
Advance HAE	HAE	Apple, Google	<ul style="list-style-type: none"> • Angioedema (duration and location) 	N = 22 ^a Others (can be entered)	School/work days missed	No	N = 7 ^b regular N = 16 ^c on demand Others (can be entered)	No	Eng	HAEA
HAERO	HAE	Apple, Google	<ul style="list-style-type: none"> • Angioedema (location) • Pain 	N = 9 ^d Others (can be entered)	School/work days missed	No	N = 5 ^e	No	Eng, Fre	AOHQ
myHAE	HAE	Apple, Google	<ul style="list-style-type: none"> • Angioedema (body part affected) 	N = 6 ^f Others (can be entered)	No	No	On demand and regular medication can be entered	No	Eng, Ger	Takeda
HAE & Me	HAE	Apple	<ul style="list-style-type: none"> • Angioedema (location) • Angioedema severity 	N = 8 ^g Others (can be entered)	No	No	N = 9 ^h	No	Eng	Pharming
TARGET My Hives	CU	Apple	<ul style="list-style-type: none"> • Urticaria severity • Angioedema severity 	N = 9 ⁱ Others (can be entered)	Yes	No	On demand medication can be entered	No	Eng, Fre, Ger, Gre, Por, Spa, Tur	Novartis
UrCare	CU	Apple, Google	<ul style="list-style-type: none"> • Urticaria severity • Angioedema severity • Number of hives 	No	QoL (CU-Q2oL)	No	Yes, access to online drug database	No	Eng, Spa	Novartis
Urticaria	CU	Google	<ul style="list-style-type: none"> • Wheals, Redness, Swellings (numbers) • Itch (duration and intensity) 	Yes (can be entered)	Yes (question 3 of UCT)	No	On demand and regular medication can be entered	No	Eng, Ger	GAAPP
UrticariApp	CU	Apple, Google	<ul style="list-style-type: none"> • Wheals (number) • Itch (severity) • Angioedema (location) 	No	Yes, can be entered	No	No	No	Eng, Spa	AAUC
SymTrac™ HIVES	CU	Google	<ul style="list-style-type: none"> • Urticaria (severity) • Angioedema severity • Number of hives 	No	QoL (DLQI)	No	No	No	Eng	Novartis

Note: For = Disease the app was developed for, that is, HAE = hereditary angioedema or CU = chronic spontaneous urticaria (all CU apps are only for patients chronic spontaneous urticaria, and not for patients with other forms of chronic urticaria); Advice = Does the app offer individualized advice to user, based on the user's data/documentation.

Abbreviations: AAS, angioedema activity score; AAUC, Asociación der Afectados de Urticaria Crónica; AOHQ, Association des Patients d'Angio-Oedeme Hereditaire du Quebec; CU-Q2oL, chronic urticaria quality of life questionnaire; DLQI, dermatologic quality of life index; Eng, English; Fre, French; Ger, German; Gre, Greek; HAEA, US Hereditary Angioedema Association; that is, yes/no = screener question, 5 follow up questions for yes; Por, Portuguese; Spa, Spanish; Tur, Turkish; GAAPP = Global Allergy and Asthma Patient Platform; UAS, urticaria activity score, that is, assessment of itch (none, mild, moderate, severe) and wheals (0, 0–19, 20–50, >50) in last 24h; UCT, urticaria control test.

^aroutine dental cleaning, other dental procedure, medical procedure, minor injury or prolonged physical pressure, infection/illness, taking birth control, menstrual period, menopause, being pregnant, fatigue, being on hormone replacement therapy, food or non-alcoholic beverages, stress, anger/frustration, lack of sleep, medication, alcohol, sadness/depression, constipation, anxiety, weather

^bandrogens, antifibrinolytics, C1-inhibitor intravenously; C1-inhibitor subcutaneously, progesterone, clinical study drug (can be typed in), lanadelumab

^cberinert, cinryze, ruconest, heagarda, kalbitor, firazyr, corticosteroids, antihistamines, clinical trial study drug (can be typed in), narcotic pain medicine, non-narcotic pain medicine, intravenous fluids, additional androgens, additional antifibrinolytics, fresh frozen plasma, epinephrine

^dstress, trauma, surgical procedures, contraceptives, angiotensin converting enzyme inhibitors, dental work, viral infections, hormone replacement therapy, unknown

^eberinert, cinryze, firazyr, heagarda, takhzyro








^finfection, stress, medical or dental procedure, trauma, flu-like symptoms, unknown

^ganxiety, stress, minor injury, dental/medical/surgical procedure, fatigue, certain medications, infection, hormonal changes

^hruconest, firazyr, kalbitor, berinert, cinryze, heagarda, takhzyro, orladeyo, generic icatibant; Remind = apps reminds user to enter data and/or to refill prescription.

ⁱscratching, cold, sun, pressure, exercise, heat, alcohol, allergies, unknown.

from Moxie, personal fees from Pharvaris, outside the submitted work. Dr. Weller reports personal fees from Biocryst, personal fees from Moxie, grants and personal fees from Novartis, grants and personal fees from Takeda, outside the submitted work. Dr. Zuberbier reports personal fees from Bayer Health Care, personal fees from FAES, grants and personal fees from Novartis, grants and personal fees from Henkel, personal fees from AstraZeneca, personal fees from AbbVie, personal fees from ALK, personal fees from Almirall, personal fees from Astellas, personal fees from Bayer Health Care, personal fees from Bencard, personal fees from Berlin Chemie, personal fees from FAES, personal fees from HAL, personal fees from Leti, personal fees from Meda, personal fees from Menarini, personal fees from Merck, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal fees from Takeda, personal fees from Teva, personal fees from UCB, personal fees from Henkel, personal fees from Kryolan, personal fees from L'Oréal, outside the submitted work; and Organizational affiliations: Committee member: WHO-Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA) Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI) Head: European Centre for Allergy Research Foundation (ECARF) President: Global Allergy and Asthma European Network (GA²LEN) Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed, MASK-air, outside the submitted work. Dr. Maurer reports grants and personal fees from Allakos, personal fees from Aralez, grants from ArgenX, grants from AstraZeneca, personal fees from Celldex, grants and personal fees from CSL Behring, grants and personal fees from FAES, grants and personal fees from Genentech, grants from Innate Pharma, personal fees from Kalvista, grants and personal fees from Kyowa Kirin, grants from Leo Pharma, grants from Lilly, grants and personal fees from Menarini, grants and personal fees from Moxie, grants and personal fees from Novartis, grants from Roche, grants and personal fees from Sanofi/Regeneron, grants and personal fees from Shire/Takeda, grants and personal fees from UCB, grants and personal fees from Uriach, outside the submitted work.

Aram Antó¹ 
 Rasmus Maurer²
 Ana Gimenez-Arnau³
 Ivan Cherez-Ojeda⁴ 
 Tomasz Hawro²
 Markus Magerl²
 Martin Metz² 
 Karsten Weller² 
 Torsten Zuberbier⁵ 
 Jean Bousquet^{5,6} 
 Marcus Maurer² 

¹MASK-air, Montpellier, France

²Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

³Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, Spain

⁴Universidad Espíritu Santo, Samborondón, Ecuador

⁵Comprehensive Allergy Centre Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

⁶Centre Hospitalier Universitaire, Montpellier, France

Correspondence

Marcus Maurer, Charité – Universitätsmedizin Berlin, Department of Dermatology and Allergy, Dermatological Allergology, Charitéplatz 1, 10117 Berlin, Germany.
 Email: marcus.maurer@charite.de

Aram Antó and Rasmus Maurer authors contributed equally.

ORCID

Aram Antó  <https://orcid.org/0000-0001-8180-5481>
 Ivan Cherez-Ojeda  <https://orcid.org/0000-0002-1610-239X>
 Martin Metz  <https://orcid.org/0000-0002-4070-9976>
 Karsten Weller  <https://orcid.org/0000-0003-4437-0313>
 Torsten Zuberbier  <https://orcid.org/0000-0002-1466-8875>
 Jean Bousquet  <https://orcid.org/0000-0002-4061-4766>
 Marcus Maurer  <https://orcid.org/0000-0002-4121-481X>

REFERENCES

- Weller K, Zuberbier T, Maurer M. Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. *Curr Opin Allergy Clin Immunol* 2015;15(3):220-226.
- Anto A, Sousa-Pinto B, Bousquet J. Anaphylaxis and digital medicine. *Curr Opin Allergy Clin Immunol* 2021;21(5):448-454.
- Cherez-Ojeda I, Vanegas E, Cherez A, et al. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. *World Allergy Organ J*. 2021;14(6):100542.
- Maurer M, Weller K, Magerl M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study. *World Allergy Organ J* 2020;13(11):100475.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.